Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pediatric Oncology · Pediatric Astrocytoma

Pediatric vs. Adult Astrocytomas: Understanding the Differences

At a Glance

Pediatric astrocytomas are biologically and genetically distinct from adult brain tumors. Instead of IDH mutations, childhood tumors are typically driven by MAPK pathway alterations like BRAF or histone mutations. Molecular testing is essential to confirm the diagnosis and identify targeted treatment options.

Note: The majority of this guide is written for adults navigating their own diagnosis. However, if you are reading this guide on behalf of a child, it is vital to know that pediatric brain tumors are not simply “adult tumors in smaller bodies.”

Finding out your child has an astrocytoma is a heavy burden to carry. In children, these tumors are fundamentally different at a biological and genetic level, often driven by specific genetic “glitches” that are rarely seen in adults [1][2]. This means the treatment approach and long-term outlook are completely unique to pediatrics [3][4].

The Two Main Categories

In pediatric neuro-oncology, doctors generally divide tumors into two groups:

  1. Circumscribed Gliomas: The most common of these is the Pilocytic Astrocytoma (Grade 1) [5]. These tumors are “circumscribed,” meaning they have a well-defined border and do not typically spread into the surrounding brain tissue [6]. Because of this, they can often be successfully managed with surgery alone if the entire tumor can be safely removed [7][8].
  2. Diffuse Gliomas: These tumors are more “infiltrative,” meaning they blend into the healthy brain tissue [9]. In the 2021 WHO classification, these are now categorized into specialized groups like Pediatric-type diffuse low-grade gliomas and Pediatric-type diffuse high-grade gliomas to reflect their unique genetics [10][11].

Pediatric-Specific Genetic Markers

While adult tumors are often defined by the IDH mutation, pediatric tumors are frequently driven by alterations in the MAPK pathway—a signaling highway that tells cells when to grow [12][9]. Key markers your child’s team will look for include:

  • BRAF Alterations: This is the most common driver in pediatric low-grade gliomas [13]. It can appear as a “fusion” (two genes stuck together, like BRAF-KIAA1549) or a “mutation” (a single error, like BRAF V600E) [14][15].
  • MYB and MYBL1: These markers are often found in certain diffuse low-grade tumors and are frequently associated with a history of seizures in children [16][17].
  • Histone Mutations (H3 K27 and H3 G34): These are found in pediatric-type high-grade gliomas [18]. For example, the H3 K27-altered tumor (often called Diffuse Midline Glioma) is a specific diagnosis that requires a different treatment strategy than adult high-grade tumors [19][20].

Why Molecular Testing is Vital

Understanding your child’s specific genetic marker is no longer “optional”—it is how the diagnosis is confirmed [1]. For example, identifying a BRAF V600E mutation may allow your child to access targeted therapies, such as MAPK inhibitors (e.g., trametinib), which have shown success in shrinking tumors or stopping their growth in clinical trials [21][22].

Because these tumors can be complex, having your child’s care managed at a dedicated pediatric brain tumor center is essential. These centers have the specialized neuropathologists and neuro-oncologists needed to interpret these molecular results and provide access to the most current pediatric-specific treatments [23][24].

Common questions in this guide

How is a pediatric astrocytoma different from an adult astrocytoma?
Pediatric astrocytomas are fundamentally different biologically and genetically. While adult tumors are often defined by IDH mutations, childhood tumors are usually driven by alterations in the MAPK pathway, such as BRAF mutations, which require specialized treatment strategies.
What is the difference between circumscribed and diffuse gliomas in children?
Circumscribed gliomas, like pilocytic astrocytomas, have well-defined borders and can often be treated successfully with surgery alone. Diffuse gliomas blend into the surrounding healthy brain tissue, making them harder to remove entirely and often requiring a different treatment approach.
Why does my child need molecular testing for an astrocytoma?
Molecular testing identifies the specific genetic errors, like BRAF or histone mutations, that are driving your child's tumor. This testing is crucial because it confirms the exact diagnosis and can qualify your child for targeted therapies designed to stop the tumor's growth.
What does a BRAF alteration mean for my child's tumor?
A BRAF alteration is a genetic error that tells tumor cells to grow, and it is the most common driver in pediatric low-grade gliomas. Knowing your child has a BRAF mutation or fusion allows doctors to determine if targeted medications, such as MAPK inhibitors, are an appropriate treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my child's tumor been tested for the BRAF V600E mutation or BRAF-KIAA1549 fusion?
  2. 2.Is this tumor considered 'circumscribed' or 'diffuse' on imaging, and how does that affect the surgery plan?
  3. 3.Do the molecular results show any MYB or MYBL1 alterations?
  4. 4.If this is a high-grade tumor, has it been tested for the H3 K27M or H3 G34 mutations?
  5. 5.Based on my child's specific MAPK pathway markers, are there targeted therapies like trametinib or dabrafenib that we should consider?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.

    Otani Y, Satomi K, Suruga Y, et al.

    Brain tumor pathology 2023; (40(2)):56-65 doi:10.1007/s10014-023-00457-6.

    PMID: 37004583
  2. 2

    Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas.

    Mirchia K, Richardson TE

    Cancers 2020; (12(7)) doi:10.3390/cancers12071817.

    PMID: 32640746
  3. 3

    2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.

    Thomas DL

    Chinese clinical oncology 2023; (12(1)):7 doi:10.21037/cco-22-120.

    PMID: 36922356
  4. 4

    Pediatric-type diffuse low-grade gliomas.

    Biswas A, Rao HR, Wagner MW

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(10)):3003-3006 doi:10.1007/s00381-024-06500-x.

    PMID: 38926169
  5. 5

    The tumour microenvironment of pilocytic astrocytoma evolves over time via enrichment for microglia.

    Stone TJ, Pickles JC, Ogunbiyi O, et al.

    Acta neuropathologica communications 2025; (13(1)):30 doi:10.1186/s40478-024-01922-9.

    PMID: 39948623
  6. 6

    Infiltration in Pilocytic Astrocytoma: A Diagnostic Pitfall.

    Alturkustani M

    Cureus 2022; (14(8)):e27940 doi:10.7759/cureus.27940.

    PMID: 36120224
  7. 7

    Comparison of the clinical features and treatment outcomes of pilocytic astrocytoma in pediatric and adult patients.

    Kim JW, Phi JH, Kim SK, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2023; (39(3)):583-591 doi:10.1007/s00381-023-05839-x.

    PMID: 36662276
  8. 8

    Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence.

    Bond KM, Hughes JD, Porter AL, et al.

    World neurosurgery 2018; (110()):276-283 doi:10.1016/j.wneu.2017.11.102.

    PMID: 29180079
  9. 9

    Pediatric-Type Diffuse Low Grade Glioma.

    Kotch C, Green K, Fisher MJ, Hargrave D

    Advances in cancer research 2025; (167()):1-35 doi:10.1016/bs.acr.2025.08.006.

    PMID: 41198334
  10. 10

    The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.

    Perez A, Huse JT

    Current neurology and neuroscience reports 2021; (21(12)):67 doi:10.1007/s11910-021-01153-8.

    PMID: 34817712
  11. 11

    Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.

    Gianno F, Giovannoni I, Cafferata B, et al.

    Pathologica 2022; (114(6)):422-435 doi:10.32074/1591-951X-830.

    PMID: 36534421
  12. 12

    Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.

    Manoharan N, Liu KX, Mueller S, et al.

    Neoplasia (New York, N.Y.) 2023; (36()):100857 doi:10.1016/j.neo.2022.100857.

    PMID: 36566593
  13. 13

    New and Emerging Therapies for Patients with Low-Grade Glioma.

    Peters KB

    CNS drugs 2026; (40(1)):1-18 doi:10.1007/s40263-025-01238-9.

    PMID: 41201564
  14. 14

    Diffuse leptomeningeal glioneuronal tumor in an 8-year-old girl: case report and review of the literature.

    Cambruzzi E, Medeiros MS, Cardoso CE, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2023; (39(1)):301-305 doi:10.1007/s00381-022-05625-1.

    PMID: 35922601
  15. 15

    BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

    Schreck KC, Grossman SA, Pratilas CA

    Cancers 2019; (11(9)) doi:10.3390/cancers11091262.

    PMID: 31466300
  16. 16

    Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.

    Qaddoumi I, Orisme W, Wen J, et al.

    Acta neuropathologica 2016; (131(6)):833-45 doi:10.1007/s00401-016-1539-z.

    PMID: 26810070
  17. 17

    The malignant transformation of an atypical angiocentric glioma, MYB-altered.

    Aboubakr O, Wefers AK, Dangouloff-Ros V, et al.

    Acta neuropathologica communications 2025; (13(1)):161 doi:10.1186/s40478-025-02070-4.

    PMID: 40702569
  18. 18

    Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.

    Kurokawa R, Hagiwara A, Ueda D, et al.

    La Radiologia medica 2025; (130(11)):1871-1887 doi:10.1007/s11547-025-02078-9.

    PMID: 40853542
  19. 19

    Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

    Karremann M, Gielen GH, Hoffmann M, et al.

    Neuro-oncology 2018; (20(1)):123-131 doi:10.1093/neuonc/nox149.

    PMID: 29016894
  20. 20

    Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.

    Sim Y, Choi SH, Lee N, et al.

    European journal of radiology 2024; (173()):111384 doi:10.1016/j.ejrad.2024.111384.

    PMID: 38422610
  21. 21

    Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.

    Paul MR, Pehlivan KC, Milburn M, et al.

    Journal of pediatric hematology/oncology 2020; (42(8)):e730-e737 doi:10.1097/MPH.0000000000001819.

    PMID: 32398601
  22. 22

    A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells.

    Usta D, Sigaud R, Buhl JL, et al.

    Molecular cancer therapeutics 2020; (19(8)):1736-1750 doi:10.1158/1535-7163.MCT-19-1021.

    PMID: 32451331
  23. 23

    Pleomorphic xanthoastrocytoma with NTRK fusion presenting as spontaneous intracranial hemorrhage-case report and literature review.

    Wu Y, Aw SJ, Jain S, et al.

    Frontiers in pediatrics 2024; (12()):1378608 doi:10.3389/fped.2024.1378608.

    PMID: 39108689
  24. 24

    Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia.

    Rajagopal R, Abd-Ghafar S, Ganesan D, et al.

    Journal of global oncology 2017; (3(2)):143-156 doi:10.1200/JGO.2015.002659.

    PMID: 28717752

This page provides educational information about the differences between pediatric and adult astrocytomas. Always consult a pediatric neuro-oncologist to interpret your child's specific tumor genetics and treatment options.

Get notified when new evidence is published on Astrocytoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.